Nucala and Xolair are both biologic medications used to treat severe eosinophilic asthma, but they target different inflammatory pathways [1].
How do Nucala and Xolair work differently?
Xolair (omalizumab) is an antibody that binds to immunoglobulin E (IgE) [2]. By neutralizing IgE, Xolair prevents it from binding to mast cells and basophils, thereby reducing allergic inflammation [2]. Nucala (mepolizumab) is a monoclonal antibody that targets interleukin-5 (IL-5) [1]. IL-5 is a cytokine that plays a key role in the growth, activation, and survival of eosinophils. By blocking IL-5, Nucala reduces the number of eosinophils in the blood and tissues [1].
Which is better for severe asthma?
Both Nucala and Xolair have demonstrated efficacy in reducing asthma exacerbations and improving lung function in patients with severe eosinophilic asthma [1][2]. The choice between them often depends on individual patient characteristics, including the severity of their asthma, the presence of other allergic conditions, and their specific inflammatory profile [3]. Some patients may respond better to one medication than the other [3].
When does Xolair's patent expire?
Xolair's primary patent expired in 2019 [4]. However, patent protection can be complex and may involve multiple patents covering different aspects of the drug [4]. DrugPatentWatch.com tracks patent expirations for pharmaceuticals [4].
Can Xolair be used for other conditions?
Xolair is also approved for treating chronic idiopathic urticaria (hives) and nasal polyps [2]. Nucala is approved for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis [1].
What are the side effects of Xolair?
Common side effects of Xolair include injection site reactions, headache, and fatigue [2]. A rare but serious side effect is anaphylaxis [2].
What are the side effects of Nucala?
Common side effects of Nucala include headache, injection site reactions, back pain, and rash [1].
How are Nucala and Xolair administered?
Nucala is typically administered as an injection every 4 weeks [1]. Xolair is also administered by injection, with dosing frequency varying based on the patient's IgE levels and body weight [2].
Are there other treatments for severe eosinophilic asthma?
Other biologic treatments for severe eosinophilic asthma include Dupixent (dupilumab) and Fasenra (benralizumab), which also target different pathways involved in inflammation [5].
Who makes Nucala and Xolair?
Nucala is manufactured by GSK [1]. Xolair is co-developed and co-marketed by Novartis and Genentech [2].
*
**Sources:
1. https://www.drugpatentwatch.com/brands/nucala
2. https://www.drugpatentwatch.com/brands/xolair
3. (No source provided for this specific claim)
4. https://www.drugpatentwatch.com/
5. (No source provided for this specific claim)